FY2026 EPS Estimates for Nanobiotix Cut by HC Wainwright

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – HC Wainwright cut their FY2026 earnings per share estimates for Nanobiotix in a report issued on Monday, March 30th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $1.05 per share for the year, down from their prior forecast of $1.06. The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Nanobiotix’s FY2028 earnings at $0.58 EPS and FY2030 earnings at $2.33 EPS.

Several other brokerages have also recently weighed in on NBTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Guggenheim increased their target price on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Nanobiotix presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Nanobiotix Stock Performance

NASDAQ NBTX opened at $31.04 on Thursday. Nanobiotix has a 52 week low of $2.99 and a 52 week high of $41.89. The stock’s 50 day moving average price is $28.10 and its two-hundred day moving average price is $23.25.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million during the quarter.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its holdings in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the last quarter. Optiver Holding B.V. acquired a new position in Nanobiotix during the third quarter worth $101,000. Marshall Wace LLP acquired a new position in Nanobiotix during the fourth quarter worth $220,000. Finally, Millennium Management LLC bought a new stake in Nanobiotix during the fourth quarter worth $390,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

More Nanobiotix News

Here are the key news stories impacting Nanobiotix this week:

• Positive Sentiment: Guggenheim raised its price target on NBTX from $26 to $36 and initiated/maintained a “Buy” rating — a supportive analyst upgrade that signals ~16% upside from the cited price and may attract fresh buying interest. Benzinga Coverage
• Positive Sentiment: HC Wainwright issued a bullish long-term EPS view, forecasting FY2030 EPS of $2.33 (well above consensus for current-year losses), which underscores expectations for meaningful recovery/value creation over the coming years. MarketBeat: HC Wainwright Estimates
• Neutral Sentiment: The Q4 2025 earnings call transcript is available for investors who want management detail on results, guidance and program timelines — useful for due diligence but not a single catalyst. Earnings Call Transcript
• Negative Sentiment: HC Wainwright trimmed its FY2028 EPS estimate to $0.58 from $0.68 — a pullback in medium-term profitability expectations that can weigh on sentiment and be a source of profit-taking. MarketBeat: Estimate Revision
• Negative Sentiment: HC Wainwright slightly lowered its FY2026 EPS estimate to $1.05 from $1.06 — a modest downgrade but consistent with the theme of trimmed near-term forecasts. MarketBeat: Estimate Revision

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.